Back
Mersana Therapeutics 10K Form
Sell
46
MRSN
Mersana Therapeutics
Last Price:
2.13
Seasonality Move:
33.27%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-08-07 | 10Q | MRSN/Mersana Therapeutics Quarterly |
2020-05-08 | 10Q | MRSN/Mersana Therapeutics Quarterly |
2020-02-28 | 10K | MRSN/Mersana Therapeutics Annual |
2019-11-06 | 10Q | MRSN/Mersana Therapeutics Quarterly |
2019-08-08 | 10Q | MRSN/Mersana Therapeutics Quarterly |
2019-05-09 | 10Q | MRSN/Mersana Therapeutics Quarterly |
Receive MRSN News And Ratings
See the #1 stock for the next 7 days that we like better than MRSN
MRSN Financial Statistics
Sales & Book Value
Annual Sales: | $36.86M |
---|---|
Cash Flow: | $-21.86M |
Price / Cash Flow: | 0 |
Annual Sales: | $0.07 |
Price / Book: | 30.86 |
Profitability
EPS (TTM): | -0.87000 |
---|---|
Net Income (TTM): | $-104.77M |
Gross Margin: | -- |
Return on Equity: | -243.31% |
Return on Assets: | -44.49% |
Mersana Therapeutics Earnings Forecast
Key Mersana Therapeutics Financial Ratios
- The Research & Development expenses have been 402.30% of Revenue.
- The Interest Expense is -2.37% of Operating Income.
- The Net Earning history of MRSN is -465.80% of Total Revenues.
- Per Share Earnings over the last 9 years have been positive in 5 years.
Mersana Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | MRSN |
CUSIP: | 59045L |
Website: | mersana.com |
Debt
Debt-to-Equity Ratio: | 3.01 |
---|---|
Current Ratio: | 2.72 |
Quick Ratio: | 2.64 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
MRSN Technical Analysis vs Fundamental Analysis
Sell
46
Mersana Therapeutics (MRSN)
is a Sell
Is Mersana Therapeutics a Buy or a Sell?
-
Mersana Therapeutics stock is rated a Sell
The current Mersana Therapeutics [MRSN] share price is $2.12. The Score for MRSN is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.